<?xml version="1.0" encoding="UTF-8"?>
<p>In the European Union, the EMA supports early patient access to new medicines and which are eligible for a marketing authorization application under the centralized procedure and either target unmet medical needs or those which have a major public health interest. The EMA has launched a priority medicines (PRIME) scheme to facilitate early dialogue and support the development of medicines that target unmet medical needs and which promotes an accelerated regulatory assessment. In addition, the PRIME scheme is intended for seriously debilitating or life‚Äêthreatening diseases, compassionate use of unauthorized medicines for patients with an unmet medical need (when no satisfactory treatment is available in the European Union) and also provides conditional marketing authorization.</p>
